Lenalidomide in Diffuse Large B-Cell Lymphomas

Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive disease. Lenalidomide, an immunomodulatory agent,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiappella, Annalisa, Vitolo, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390034/
https://www.ncbi.nlm.nih.gov/pubmed/22792112
http://dx.doi.org/10.1155/2012/498342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390034/
https://www.ncbi.nlm.nih.gov/pubmed/22792112
http://dx.doi.org/10.1155/2012/498342

Ejemplares similares